We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pay-for-delay deals between branded and generic drugmakers in the European Union continued to decline in 2016, according to the latest update from the European Commission. Read More
Osiris Therapeutics filed a lawsuit against MiMedx Group for alleged theft of its clients and pre-paid commissions to Osiris’ longtime distributor Stability Biologics. Read More
U.S. drugmakers could be impacted by the Trump administration’s proposed tariff on thousands of Chinese goods, which includes pharmaceutical products and ingredients used in drug manufacturing — including epinephrine, psychotherapeutic agents, antidepressants and lidocaine, among others. Read More
A federal appeals court delayed a Patent Trial and Appeals Board review of Allergan’s patents for its dry-eye drug Restasis until after a court hears oral arguments on jurisdictional issues. Read More
The prices of 20 top-selling branded drugs increased at 10 times the price of inflation from 2012 to 2017, according to a new report released by Sen. Claire McCaskill (D-Mo.). Read More
The first trial in multi-district litigation over claims the antipsychotic drug Abilify caused compulsive behavior must proceed in June, a federal judge has ruled. Read More
Doctors are five times more likely to prescribe a brand name drug if they receive payments from a pharmaceutical company for that drug, and the likelihood increases to 14.5 times for specific opioids, according to a new analysis from CareDash. Read More
The lawsuit cites examples, including a November 2014 incident when a plaintiff paid the pharmacy a $20 copay for amlodipine besylate, a 1,043 percent markup from the $1.75 paid to the pharmacist. Read More
A federal judge refused a motion by CIGNA to dismiss a class-action lawsuit alleging it artificially inflated the cost of prescription drugs. Read More